Prof. Dr. Rainer Fietkau

Lehrstuhl für Strahlentherapie

Combinations of radiotherapy with vaccination and immune checkpoint inhibition differently affect primary and abscopal tumor growth and the tumor microenvironment (2021) Rückert M, Deloch L, Frey B, Schlücker E, Fietkau R, Gaipl U Journal article Increase in non-professional phagocytosis during the progression of cell cycle (2021) Hofmann A, Putz F, Büttner-Herold M, Hecht M, Fietkau R, Distel L Journal article Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial (2021) Kosmala R, Fokas E, Flentje M, Sauer R, Liersch T, Graeven U, Fietkau R, et al. Journal article Behandlungsstrategie beim radiojodrefraktären differenzierten Schilddrüsenkarzinom (2021) Mantsopoulos K, Müller SK, Pavel ME, Kuwert T, Meidenbauer N, Fietkau R, Sievert M, Iro H Journal article Volumetric Regression in Brain Metastases After Stereotactic Radiotherapy: Time Course, Predictors, and Significance (2021) Oft D, Schmidt M, Weissmann T, Roesch J, Mengling V, Masitho S, Bert C, et al. Journal article The Distribution of Pelvic Nodal Metastases in Prostate Cancer Reveals Potential to Advance and Personalize Pelvic Radiotherapy (2021) Filimonova I, Schmidt D, Mansoorian S, Weissmann T, Siavooshhaghighi H, Kuwert T, Bert C, et al. Journal article Integration of radiation oncology teaching in medical studies by German medical faculties due to the new licensing regulations: An overview and recommendations of the consortium academic radiation oncology of the German Society for Radiation Oncology (DEGRO) (2021) Dapper H, Belka C, Bock F, Budach , Budach W, Christiansen H, Debus J, et al. Journal article Head and neck tumor cells treated with hypofractionated irradiation die via apoptosis and are better taken up by M1-like macrophages (2021) Wedekind H, Walz K, Buchbender M, Rieckmann T, Strasser E, Grottker F, Fietkau R, et al. Journal article PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (2021) Girard N, Smit HJM, Sibille A, Mcdonald F, Mornex F, Garassino MCC, Filippi AR, et al. Conference contribution Results of a randomized phase II study comparing pembrolizumab with methotrexate in elderly, frail or cisplatin-ineligible patients with relapsed or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) (ELDORANDO-AIO-KHT-0115) (2021) Gruenwald V, Graeven U, Ivanyi P, Dietz A, Hahn D, Hackenberg S, Kasper S, et al. Conference contribution